文献速递胃肠外科围术期管理与 ERAS

美国减重手术后患者GLP-1受体激动剂使用情况

Use of Glucagon-Like Peptide-1 Agonists Among Individuals Undergoing Bariatric Surgery in the US.
PubMed 文献 · JAMA Surg · 2025-01-01

结果显示14.0%的患者术后启动GLP-1,女性、袖状胃切除及2型糖尿病患者更易启动,术后BMI每升高1单位启动可能性增加8%。

要点

  • 约14.0%的减重手术患者术后启动GLP-1,多数在术后3年以上启动。
  • 女性、袖状胃切除、2型糖尿病患者的GLP-1启动风险更高。
  • 术后BMI每升高1单位,GLP-1启动可能性增加8%。

核心结论

  • 美国减重手术人群中约十分之一术后启动GLP-1,女性、袖状胃切除及体重反弹更明显者启动更多。

主要发现

  • 其余启动者分布于术后3至4年(5082例,32.3%)、5至6年(3964例,25.2%)及更晚(3312例,21.0%)。
  • 启动GLP-1前总体BMI中位数(IQR)为42.0(38.3-45.6)。
  • 女性(aHR 1.61;95%CI 1.54-1.69)、袖状胃切除(aHR 1.42;95%CI 1.37-1.47)、2型糖尿病(aHR 1.34;95%CI 1.28-1.39)与启动风险升高相关。
  • 术后BMI每增加1单位,启动GLP-1的可能性增加8%(aHR 1.08;95%CI 1.08-1.08)。

临床怎么用

  • 减重术后随访应关注体重反弹,尤其女性、袖状胃切除及2型糖尿病患者,及时评估GLP-1辅助减重的可能。

局限性

  • 为回顾性队列研究,仅能提示关联而不能确立因果。
  • 数据来自电子健康记录数据库,可能存在未测量的混杂与用药记录不全。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although randomized and well-controlled observational studies demonstrate the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1s) for weight management after bariatric surgery, little is known regarding the frequency and predictors of such use. OBJECTIVE: To characterize the use of and factors associated with GLP-1 initiation among US adults undergoing bariatric surgery. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted using a national multicenter database of electronic health records of approximately 113 million US adults. Adults undergoing bariatric surgery from January 2015 to May 2023 who did not use GLP-1s during the 12 months prior to surgery were eligible for inclusion. Data were analyzed from October 2024 to May 2025. EXPOSURES: Sociodemographic factors (age, sex, race, region, etc) and clinical factors (bariatric surgery procedures, body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], comorbidities, comedications). MAIN OUTCOMES AND MEASURES: The primary outcome was GLP-1 initiation after bariatric surgery, first characterized using descriptive statistics. Cox proportional hazards models were then used to identify baseline patient characteristics associated with GLP-1 initiation. Time-dependent Cox models were also used to examine the association of postsurgery BMI with GLP-1 initiation. RESULTS: Among 112 858 individuals undergoing bariatric surgery, mean (SD) age was 45.2 (12.9) years, and 88 994 individuals (78.9%) were female. By self-reported race, 1210 individuals (1.1%) were Asian, 24 941 (22.1%) were Black or African American, 72 423 (64.2%) were White, and 14 284 (12.6%) reported other race (American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, or unknown). A total of 15 749 individuals (14.0%) initiated GLP-1s after surgery, with 3391 (21.5%) beginning within 2 years of surgery and the remainder initiating during postsurgical years 3 to 4 (5082 [32.3%]), years 5 to 6 (3964 [25.2%]), or beyond (3312 [21.0%]). The overall median (IQR) BMI before GLP-1 initiation was 42.0 (38.3-45.6). In regression models, female patients (adjusted hazard ratio [aHR], 1.61; 95% CI, 1.54-1.69), those undergoing sleeve gastrectomy (aHR, 1.42; 95% CI, 1.37-1.47), and those with type 2 diabetes (aHR, 1.34; 95% CI, 1.28-1.39) were more likely to initiate GLP-1s than their counterparts. Each 1-unit increase in postsurgical BMI was associated with an 8% increase in likelihood of GLP-1 initiation (aHR, 1.08; 95% CI, 1.08-1.08). CONCLUSIONS AND RELEVANCE: In this retrospective cohort study using a nationwide database, among a cohort of US adults undergoing bariatric surgery, approximately 1 in 10 initiated a GLP-1. Initiation was greater among women, those undergoing sleeve gastrectomy, and individuals with larger BMI regain than among their counterparts.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Kim M, Schweitzer MA, Kim JS, et al. Use of Glucagon-Like Peptide-1 Agonists Among Individuals Undergoing Bariatric Surgery in the US. JAMA Surg. 2025. PMID: 40864458. doi:10.1001/jamasurg.2025.3089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。